The device will allow cardiac surgeons to occlude the left atrial appendage, a small muscular pouch attached to the left atrium of the heart.

AtriCure CEO Mike Carrel said the company is dedicated to develop medical devices that solve complex problems and improve the lives of patients.

"AtriClip FLEX is a good example of how we listen and respond to the unique needs of surgeons," Carrel added.

The firm’s AtriClip has received FDA approval for the occlusion of the Left Atrial Appendage Management (LAAM) under direct visualization, in conjunction with other open cardiac surgical procedures.

The LAAM Exclusion System portfolio comprises AtriClip PRO, AtriClip long and AtriClip standard, which have different lengths and deployment features.

AtriCure also produces Synergy Ablation System, which is used to treat Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures.

The device is currently available in the US, while it will be available in Europe and other geographies later this year.